Spots Global Cancer Trial Database for stage iva laryngeal cancer ajcc v8

Every month we try and update this database with for stage iva laryngeal cancer ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT05172245	Clinical Stage ... Head and Neck C... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Maxillary Sinus... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage III Sinon... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oroph... Stage IVA Sinon... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Oroph... Stage IVB Sinon...	Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Ipatasertib Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin	NCT04533750	Advanced Head a... Advanced Hypoph... Advanced Laryng... Advanced Oral C... Advanced Oropha... Clinical Stage ... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Oroph...	Computed Tomogr... Fludeoxyglucose... Intensity-Modul... Magnetic Resona... Peposertib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin	NCT04533750	Advanced Head a... Advanced Hypoph... Advanced Laryng... Advanced Oral C... Advanced Oropha... Clinical Stage ... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Oroph...	Computed Tomogr... Fludeoxyglucose... Intensity-Modul... Magnetic Resona... Peposertib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin	NCT03258554	Clinical Stage ... Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Oral Cavity Squ... Oropharyngeal S... Pathologic Stag... Squamous Cell C... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Oroph...	Cetuximab Durvalumab Intensity-Modul... Laboratory Biom... Quality-of-Life... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery	NCT02734537	Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Laryngeal Squam... Lip and Oral Ca... p16INK4a Negati... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oral ... Stage III Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oral ... Stage IVA Oroph...	Cisplatin Intensity-Modul... Laboratory Biom...	18 Years -	Eastern Cooperative Oncology Group
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer	NCT03010150	Carcinoma of Un... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Head... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage I Hypopha... Stage I Nasopha... Stage II Hypoph... Stage II Laryng... Stage II Nasoph... Stage II Oropha... Stage III Hypop... Stage III Laryn... Stage III Nasop... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Nasoph... Stage IV Oropha... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Nasop... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Nasop... Stage IVB Oroph...	Biospecimen Col... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT04862650	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Pathologic Stag... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Lip a...	Carboplatin Cemiplimab Paclitaxel	18 Years -	Ohio State University Comprehensive Cancer Center
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer	NCT04162873	Clinical Stage ... Clinical Stage ... Nasal Cavity an... Oral Cavity Car... Pathologic Stag... Pathologic Stag... Recurrent Hypop... Recurrent Laryn... Recurrent Nasal... Recurrent Oral ... Recurrent Oroph... Stage III Hypop... Stage III Laryn... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oropha... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oroph...	Celecoxib Placebo Quality-of-Life... Questionnaire A...	18 Years -	University of Utah
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT04862650	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Pathologic Stag... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Lip a...	Carboplatin Cemiplimab Paclitaxel	18 Years -	Ohio State University Comprehensive Cancer Center
Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment	NCT04788264	Head and Neck C... Hypopharyngeal ... Laryngeal Carci... Maxillary Sinus... Oral Cavity Car... Oropharyngeal C... Paranasal Sinus... Sinonasal Carci... Stage I Larynge... Stage II Laryng... Stage III Laryn... Stage IV Laryng... Stage IVA Laryn... Stage IVB Laryn... Stage IVC Laryn... Lung Carcinoma	Medical Device ... Consultation Exercise Interv... Behavioral Inte... Questionnaire A... Quality of Life...	18 Years -	Thomas Jefferson University
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery	NCT02734537	Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Laryngeal Squam... Lip and Oral Ca... p16INK4a Negati... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oral ... Stage III Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oral ... Stage IVA Oroph...	Cisplatin Intensity-Modul... Laboratory Biom...	18 Years -	Eastern Cooperative Oncology Group

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: